A phase 1 trial evaluated milciclib (PHA-848125AC), which is a pan inhibitor of the cyclin D-dependent kinases Src and TrkA, in patients with advanced or metastatic solid tumors and noted a partial response and stable disease in two patients with thymic carcinoma, resulting in further evaluation [126]. Here, NTRK1 is linked to thymic carcinoma.